---
title: "FDA approves Moderna’s mRNA flu vaccine mFLUSIVA for adults 50+: what clinicians should know"
id: "medical-news-today-0-moderna-s-mrna-flu-vaccine-approved-by-fda-when-is-it-available"
canonical_url: "https://medichelpline.com/clinical-feed/medical-news-today-0-moderna-s-mrna-flu-vaccine-approved-by-fda-when-is-it-available"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "Medical News Today"
source_url: "https://www.medicalnewstoday.com/articles/modernas-mrna-flu-vaccine-approved-fda-when-available/"
published_at: "2026-08-23T10:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# FDA approves Moderna’s mRNA flu vaccine mFLUSIVA for adults 50+: what clinicians should know
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medical-news-today-0-moderna-s-mrna-flu-vaccine-approved-by-fda-when-is-it-available
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** Medical News Today
- **Source URL:** [Original Journal Publication](https://www.medicalnewstoday.com/articles/modernas-mrna-flu-vaccine-approved-fda-when-available/)
- **Published At:** 2026-08-23T10:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The FDA has approved Moderna’s mRNA influenza vaccine **mFLUSIVA (mRNA-1010)** for adults aged 50 years and older; accelerated approval was granted for adults 65 and older. - Approval for ages 50–64 was supported by a randomized phase 3 trial of more than **40,000** adults across 11 countries comparing mFLUSIVA with a standard-dose licensed flu vaccine. - The phase 3 program found mFLUSIVA to be **superior** to a standard-dose vaccine for preventing RT-PCR–confirmed influenza, with an observed **approximately 27%** greater relative vaccine efficacy in the 50–64 age group reported in the trial. - Accelerated approval for adults ≥65 was based on a separate study of over **2,900** U.S. adults comparing immune responses with mFLUSIVA to a high-dose inactivated flu vaccine; post-approval confirmatory evidence is required for this age group. - mRNA manufacturing can be completed faster than traditional egg-based vaccine production, which may help match vaccines to rapidly changing influenza strains. - Public-health context: in the 2024–2025 U.S. season there were an estimated **45,000** flu-related deaths, and vaccination was estimated to have prevented about **12,000** deaths. - Common adverse events reported in Moderna’s trials included **headache, fatigue, joint pain, muscle pain, nausea, vomiting, fever, chills**, and injection-site reactions; rare severe allergic reactions such as anaphylaxis are possible. - Moderna recommends precautions including informing clinicians about prior vaccine allergic reactions, immunocompromise, prior Guillain-Barré syndrome after a flu vaccine, and pregnancy or breastfeeding; mFLUSIVA is not recommended for those with severe reactions to its ingredients. - Experts quoted in the article view mFLUSIVA as an important new option in influenza prevention, but caution that it is not necessarily the single best vaccine for every older adult and that further real-world outcome data, especially in those ≥65, are needed. - Moderna expects mFLUSIVA to be available in the United States for the **2026–2027** respiratory virus season; clinicians should prioritize ensuring patients receive an appropriate flu vaccine for that season rather than waiting for a specific product.
## Clinical Analysis & Structured Key Points
[Medical News Today](https://www.medicalnewstoday.com/) * Health Conditions Health Conditions * [Alzheimer's & Dementia](https://www.medicalnewstoday.com/alzheimers-and-dementia) * [Anxiety](https://www.medicalnewstoday.com/anxiety) * [Asthma & Allergies](https://www.medicalnewstoday.com/asthma-and-allergies) * [Atopic Dermatitis](https://www.medicalnewstoday.com/program/investigating-atopic-dermatitis) * [Breast Cancer](https://www.medicalnewstoday.com/breast-cancer) * [Cancer](https://www.medicalnewstoday.com/cancer) * [Cardiovascular Health](https://www.medicalnewstoday.com/cardiovascular-health) * [COVID-19](https://www.medicalnewstoday.com/coronavirus?correlationId=2b137d5a-dcfb-464e-9ea6-72c5a54b4e92) * [Diabetes](https://www.medicalnewstoday.com/diabetes) * [Endometriosis](https://www.medicalnewstoday.com/endometriosis) * [Environment & Sustainability](https://www.medicalnewstoday.com/environment-and-sustainability) * [Exercise & Fitness](https://www.medicalnewstoday.com/exercise-and-fitness) * [Eye Health](https://www.medicalnewstoday.com/eye-health) * [Headache & Migraine](https://www.medicalnewstoday.com/headache-and-migraine) * [Health Equity](https://www.medicalnewstoday.com/health-equity) * [HIV & AIDS](https://www.medicalnewstoday.com/hiv-and-aids) * [Human Biology](https://www.medicalnewstoday.com/human-biology) * [Leukemia](https://www.medicalnewstoday.com/leukemia) * [LGBTQIA+](https://www.medicalnewstoday.com/LGBTQIA) * [Men's Health](https://www.medicalnewstoday.com/mens-health) * [Mental Health](https://www.medicalnewstoday.com/mental-health) * [Multiple Sclerosis (MS)](https://www.medicalnewstoday.com/multiple-sclerosis) * [Nutrition](https://www.medicalnewstoday.com/nutrition) * [Parkinson's Disease](https://www.medicalnewstoday.com/parkinsons-disease) * [Psoriasis](https://www.medicalnewstoday.com/psoriasis) * [Sexual Health](https://www.medicalnewstoday.com/sexual-health) * [Ulcerative Colitis](https://www.medicalnewstoday.com/program/investigating-ulcerative-colitis) * [Women's Health](https://www.medicalnewstoday.com/womens-health) * Health Products Health Products [All](https://www.medicalnewstoday.com/products-and-reviews) * [Nutrition & Fitness](https://www.medicalnewstoday.com/products-and-reviews/nutrition-and-fitness-products) * [Vitamins & Supplements](https://www.medicalnewstoday.com/products-and-reviews/vitamin-and-supplement-products) * [CBD](https://www.medicalnewstoday.com/products-and-reviews/cbd-products) * [Sleep](https://www.medicalnewstoday.com/products-and-reviews/sleep-products) * [Mental Health](https://www.medicalnewstoday.com/products-and-reviews/mental-health-services-and-products) * [At-Home Testing](https://www.medicalnewstoday.com/products-and-reviews/at-home-testing-products) * [Men’s Health](https://www.medicalnewstoday.com/products-and-reviews/mens-health-products) * [Women’s Health](https://www.medicalnewstoday.com/products-and-reviews/womens-health-products) * Discover News * [Latest News](https://www.medicalnewstoday.com/news) * [Medicare 2026 Costs](https://www.medicalnewstoday.com/articles/medicare-costs-3-key-changes-in-2026) Original Series * [Medical Myths](https://www.medicalnewstoday.com/content-series/medical-myths) * [Honest Nutrition](https://www.medicalnewstoday.com/content-series/honest-nutrition) * [Through My Eyes](https://www.medicalnewstoday.com/content-series/through-my-eyes) * [New Normal Health](https://www.medicalnewstoday.com/content-series/new-normal-health) Podcasts [All](https://www.medicalnewstoday.com/articles/in-conversation-podcast) * [ADHD in women: Breaking the stereotypes](https://www.medicalnewstoday.com/articles/adhd-women-breaking-stereotypes-masking-attention-disorder) * [Is sleep the missing piece in mental health?](https://www.medicalnewstoday.com/articles/is-sleep-the-missing-piece-in-mental-health) * [Artificial sweeteners and brain aging: What we know so far](https://www.medicalnewstoday.com/articles/artificial-sweeteners-and-brain-aging-what-we-know-so-far) * [Does the Mediterranean diet hold the key to longevity?](https://www.medicalnewstoday.com/articles/does-the-mediterranean-diet-hold-the-key-to-longevity) * [AMA: Registered dietitian answers 5 key questions about fiber and weight loss](https://www.medicalnewstoday.com/articles/can-fiber-help-lose-weight-dietitian-answers-5-key-questions) * [Health misinformation and disinformation: How to avoid it](https://www.medicalnewstoday.com/articles/health-misinformation-and-disinformation-how-to-avoid-it) * Tools General Health * [Drugs A-Z](https://www.medicalnewstoday.com/drugs) * [Health Hubs](https://www.medicalnewstoday.com/articles/content-hubs) * [Newsletter](https://www.medicalnewstoday.com/newsletter) * [Medicare Plans by State](https://www.medicalnewstoday.com/about/health-medicare-state-coverage) Health Tools * [Find a Doctor](https://connect.medicalnewstoday.com/) * [BMI Calculators and Charts](https://www.medicalnewstoday.com/articles/323586) * [Blood Pressure Chart: Ranges and Guide](https://www.medicalnewstoday.com/articles/327077) * [Breast Cancer: Self-Examination Guide](https://www.medicalnewstoday.com/articles/316898) * [Sleep Calculator](https://www.medicalnewstoday.com/articles/sleep-calculator) Quizzes * [RA Myths vs Facts](https://www.medicalnewstoday.com/articles/science-fact-or-fiction-separating-ra-myths-from-facts#1) * [Type 2 Diabetes: Managing Blood Sugar](https://www.medicalnewstoday.com/articles/managing-blood-sugar-type-2-diabetes-quiz#1) * [Ankylosing Spondylitis Pain: Fact or Fiction](https://www.medicalnewstoday.com/articles/complementary-therapies-for-as-quiz#1) * Connect About Medical News Today * [Who We Are](https://www.medicalnewstoday.com/about) * [Our Editorial Process](https://www.medicalnewstoday.com/articles/process) * [Content Integrity](https://www.medicalnewstoday.com/about/content-integrity) * [Conscious Language](https://www.medicalnewstoday.com/about/conscious-language) Find Community * [Bezzy Breast Cancer](https://www.bezzybc.com/lp/2/?verzenio&utm_source=mnt&utm_medium=nav-bar-connect) * [Bezzy MS](https://www.bezzyms.com/?utm_source=mnt&utm_medium=nav-bar-connect) * [Bezzy Migraine](https://www.bezzymigraine.com/?utm_source=mnt&utm_medium=nav-bar-connect) * [Bezzy Psoriasis](https://www.bezzypsoriasis.com/?utm_source=mnt&utm_medium=nav-bar-connect) Follow Us [](https://www.facebook.com/MedicalNewsToday/)[](https://x.com/mnt)[](https://www.instagram.com/medicalnewstoday/)[](https://www.linkedin.com/company/mednewstoday/?originalSubdomain=ec)[](https://flipboard.com/@MedNewsToday) Subscribe # Moderna's mRNA flu vaccine approved by FDA. When is it available? Written by Amy McLean on August 23, 2026 — Fact checked by Jill Seladi-Schulman, Ph.D. ![A older woman is getting a vaccine.](https://media.post.rvohealth.io/wp-content/uploads/sites/3/2026/08/getty_2258370665_header_1296x728-1024x575.jpg)[Share on Pinterest](https://www.pinterest.com/pin/create/button/?url=https%3A%2F%2Fwww.medicalnewstoday.com%2Farticles%2Fmodernas-mrna-flu-vaccine-approved-fda-when-available&media=https%3A%2F%2Fmedia.post.rvohealth.io%2Fwp-content%2Fuploads%2Fsites%2F3%2F2026%2F08%2Fgetty_2258370665_header_1296x728-1024x575.jpg&description=New%20flu%20vaccine%3A%20Moderna's%20mRNA%20vaccine%20approved%20by%20FDA "Share on Pinterest")Moderna’s new mRNA flu vaccine has been approved by the FDA for adults ages 50 years and older. FatCamera, E+/Getty Images * **The Food and Drug Administration (FDA) has approved Moderna’s mFLUSIVA, the first mRNA-based flu vaccine, for adults ages 50 and older.** * **mRNA flu vaccines can be produced more quickly than traditional egg-based vaccines, which may help with matching to rapidly changing influenza virus strains.** * **Experts advise that mFLUSIVA provides another option protecting against flu, but it should not replace every flu vaccine.** The FDA has recently approved [Moderna’s mRNA flu vaccine](https://feeds.issuerdirect.com/news-release.html?newsid=4801915282452025). The vaccine, known as mFLUSIVA (mRNA-1010), is designed to protect adults ages [50 years and olderTrusted Source](https://www.fda.gov/vaccines-blood-biologics/vaccines/mflusiva) against seasonal flu. It is the first mRNA-based flu vaccine, using similar technology as the [mRNA COVID-19 vaccine](https://www.medicalnewstoday.com/articles/moderna-vaccine-for-coronavirus). The FDA approved the vaccine based on the results of a [phase 3 clinical trial](https://www.nejm.org/doi/10.1056/NEJMoa2516491) involving more than 40,000 adults ages 50 and older across 11 countries. Around half of the participants received mFLUSIVA, and the other half received a standard-dose licensed flu vaccine. The researchers concluded that mFLUSIVA was superior to the standard-dose licensed flu vaccine in preventing flu-like illness confirmed by real-time polymerase chain reaction (RT-PCR) lab tests. The vaccine was also granted accelerated approval for use in adults ages 65 years and older. This was following a [clinical trial](https://www.sciencedirect.com/science/article/pii/S0264410X25001446) involving over 2,900 adults in the United States. The study evaluated how well the immune system responded to mFLUSIVA compared with a high dose inactivated flu shot. Moderna expects that mFLUSIVA will be available in the United States for the 2026 to 2027 respiratory virus season. ## How important is the development of mFLUSIVA? There were an estimated 45,000 flu-related deaths in the United States in the 2024 to 2025 flu season, according to the most recent data from the [Centers for Disease Control and Prevention (CDC)Trusted Source](https://www.cdc.gov/flu-burden/php/data-vis-vac/2024-2025-prevented.html). They noted that vaccination was estimated to have prevented around 12,000 deaths. As the research found that mFLUSIVA has the potential to be more effective at reducing the risk of flu than other vaccines, it could help further prevent flu-related deaths. _Medical News Today_ spoke with [Dung Trinh](https://www.memorialcare.org/providers/dung-trinh), MD, internist, of MemorialCare Medical Group and Chief Medical Officer of Healthy Brain Clinic in Irvine, CA, about the importance of this latest vaccine. Trinh, who was not involved in the trials, viewed the FDA approval of mFLUSIVA as “an important addition to our influenza prevention toolkit, particularly because adults over 50 begin to experience a progressively higher risk of serious complications from influenza.” He added: “This is also a significant scientific milestone because it is the first mRNA-based seasonal influenza vaccine approved in the United States, showing that mRNA technology can be applied beyond COVID-19.” [David Cutler](https://www.providence.org/doctors/family-medicine/ca/santa-monica/david-cutler-1255368338), MD, board certified family medicine physician at Providence Saint John’s Health Center in Santa Monica, CA, also spoke with _MNT_ about the new vaccine. “My overall view is cautiously favorable. The FDA approval of Moderna’s mFLUSIVA (mRNA-1010) is scientifically interesting and potentially important, but I would not interpret it as proof that the mRNA vaccine is necessarily the best flu vaccine for every person over 50,” said Cutler, who was not involved in the trials. He also explained that the FDA’s approval has important distinctions, with “traditional/full approval” for people aged 50 to 64, and “accelerated approval, with a requirement for additional post-approval evidence confirming clinical effectiveness” for adults ages 65 and over. “That distinction matters,” continued Cutler, “because people ≥65 are the group in which we most want to know whether the vaccine actually prevents hospitalization, pneumonia, and death, rather than simply producing higher antibody levels.” ## Why is it important that the mRNA flu vaccine can match influenza strains more quickly? Flu viruses are [constantly changingTrusted Source](https://www.cdc.gov/flu/php/viruses/change.html). This means that, by the time manufacturing is finished and the vaccines are ready to be administered, the virus may have altered, and the shot might not be as effective as it would have been at the beginning of the manufacturing process. It can take at least 6 months to manufacture a traditional egg-based flu vaccine, according to the [FDATrusted Source](https://www.fda.gov/consumers/consumer-updates/fdas-critical-role-ensuring-safe-and-effective-flu-vaccines). However, the mRNA vaccine can be produced more quickly, which means it may be more likely to keep up with the rapid changes of the virus. Cutler described “a potentially important technological advantage” of the mRNA vaccine, explaining that they “can theoretically be redesigned and manufactured more rapidly when influenza strains change. That could become increasingly valuable for influenza, where vaccine-virus mismatch is a perennial problem.” [![GET CARE NOW](https://media.post.rvohealth.io/2kLEJX4A3LDe7GGDNr31WST2A26/2026/04/15/3CPSn3rbssfFZAPfhwwWP7L7mZK.png)](https://www.teladochealth.com/start?utm_campaign=tdh-healthline-native-gm&utm_content=tdh-gm-product&utm_medium=partnerships&utm_source=tdh-healthline-gm&rvo_aff=1&rvo_brandid=Teladoc&rvo_prodid=25499c9a-4dd0-4290-a20b-2cd856ecd26a&rvo_subid=e%3Ahw_s%3Amnt_n%3Acoldflu_b%3ATeladoc_g%3Aus_d%3Aall_l%3Afirst_c%3Aff_i%3A_v%3Aproduct_54162&rvo_subid2=%2Farticles%2Fmodernas-mrna-flu-vaccine-approved-fda-when-available&rvo_sys=mar&noFollowParam=1&transit_id=961ad466-4fd7-4306-a3f1-01b0d73c368b&transit_id=961ad466-4fd7-4306-a3f1-01b0d73c368b&correlationId=1684da34-5751-406d-95ee-d117eb0d122a) ADVERTISEMENT Don't wait for an appointment with 24/7 care Talk to a provider in minutes from your phone. Get care for colds, coughs, flu, stomach bugs, rashes and more. Available with or without insurance. [GET CARE NOW](https://www.teladochealth.com/start?utm_campaign=tdh-healthline-native-gm&utm_content=tdh-gm-product&utm_medium=partnerships&utm_source=tdh-healthline-gm&rvo_aff=1&rvo_brandid=Teladoc&rvo_prodid=25499c9a-4dd0-4290-a20b-2cd856ecd26a&rvo_subid=e%3Ahw_s%3Amnt_n%3Acoldflu_b%3ATeladoc_g%3Aus_d%3Aall_l%3Afirst_c%3Aff_i%3A_v%3Aproduct_54162&rvo_subid2=%2Farticles%2Fmodernas-mrna-flu-vaccine-approved-fda-when-available&rvo_sys=mar&noFollowParam=1&transit_id=961ad466-4fd7-4306-a3f1-01b0d73c368b&transit_id=961ad466-4fd7-4306-a3f1-01b0d73c368b&correlationId=1684da34-5751-406d-95ee-d117eb0d122a) As low as $0 * * * 97% satisfaction rate * * * 100 million members ## Will the mRNA flu vaccine be more effective than the traditional flu vaccine? Based on study findings, the mRNA flu vaccine has the potential to be more effective than traditional flu vaccines. “For adults ages 50 to 64, the approval was based on a randomized phase 3 trial involving more than 40,000 participants, in which mFLUSIVA demonstrated [approximately 27%](https://www.nejm.org/doi/10.1056/NEJMoa2516491) greater relative vaccine efficacy against confirmed influenza compared with a standard-dose flu vaccine, while the clinical program identified no new safety concerns,” explained Trinh. “I think the larger significance of mFLUSIVA may ultimately be beyond influenza itself,” added Cutler. “If mRNA technology proves capable of producing more effective, rapidly updated influenza vaccines, it could substantially change how we respond to seasonal influenza and potentially to future influenza pandemics,” he said. ## Are there any side effects of the mRNA flu vaccine? Like any vaccine, the mRNA flu vaccine may lead to side effects. According to Moderna, general side effects that were reported in the clinical trials included: * headache * fatigue * joint pain * muscle pain * nausea * vomiting * fever * chills There were also reactions at the injection site. In rare cases, a severe allergic reaction or [anaphylaxis](https://www.medicalnewstoday.com/articles/216062) could occur. ### Precautions to take Before getting the mRNA flu vaccine, Moderna recommends informing a healthcare professional if: * an allergic reaction to any other vaccine has ever occurred * the individual is immunocompromised or taking medication that affects the immune system * they have had Guillain-Barré syndrome after receiving a flu vaccine * they are pregnant or nursing, or if they plan to become pregnant Moderna advises against getting mFLUSIVA if the person has had a severe reaction to any of its ingredients. As with any vaccine, a healthcare professional can advise on its safety and whether they recommend it based on individual circumstances. For individuals ages 50 years and over, they can speak with their doctor about the type of flu vaccine they recommend and when they should receive it. ## Will mFLUSIVA replace traditional flu vaccines? The mRNA flu vaccine is not designed to immediately replace traditional flu vaccines. “I think the appropriate way to view this is not as a replacement for every existing flu vaccine, but as another evidence-based option that could ultimately give physicians and patients more choices in protecting people at higher risk from influenza,” Trinh explained. Cutler said, “mFLUSIVA is an exciting new option, and its trial results are encouraging. But because its FDA approval in ≥65 is accelerated and confirmatory clinical-outcome data are still required, I would want to see another season or two of real-world evidence before declaring it superior to the established enhanced vaccines.” He added: “For the 2026 to 2027 season, the most important decision is still to get an appropriate flu vaccine rather than waiting for the ‘perfect’ vaccine. The new mRNA option gives physicians and patients another potentially very useful tool.” ADVERTISEMENT The best of health and wellness ![](https://media.post.rvohealth.io/2kLEJX4A3LDe7GGDNr31WST2A26/2026/04/15/3CPTxo96sBTkyk2mretA7FzhovR.png) ![](https://media.post.rvohealth.io/2kLEJX4A3LDe7GGDNr31WST2A26/2026/04/15/3CPTxDhrzOCw2HJuSUsYLCTHuPC.png) **_Great for 24/7 access to trusted care_** * Connect by phone or video in minutes * Get care for colds, coughs, flu, stomach bugs, rashes and more * Available with or without insurance * Visits as low as $0 [GET CARE NOW](https://www.teladochealth.com/start?utm_campaign=tdh-healthline-widget-gm&utm_content=tdh-gm-product&utm_source=tdh-healthline-gm&utm_medium=partnerships&rvo_aff=1&rvo_brandid=Teladoc&rvo_prodid=f6b50f97-64e4-4007-844c-371fb4ce6208&rvo_subid=f6b50f97-64e4-4007-844c-371fb4ce6208&rvo_subid2=/articles/modernas-mrna-flu-vaccine-approved-fda-when-available&correlationId=d8f5a2f9-0a84-4f13-91c4-4a490947f671) ![](https://media.post.rvohealth.io/2kLEJX4A3LDe7GGDNr31WST2A26/2024/11/12/2olMPlBWyFDKNiN4QEb3jEOdX43.png) ### The best of health and wellness We do the research so you don't have to. Stay in the know with the latest in health and wellness. Enter your email JOIN NOW Your [privacy](https://www.medicalnewstoday.com/about/privacy-notice) is important to us * [Flu / Cold / SARS](https://www.medicalnewstoday.com/categories/flu-sars) * [Infectious Diseases / Bacteria / Viruses](https://www.medicalnewstoday.com/categories/infectious_diseases) * [Flu](https://www.medicalnewstoday.com/categories/flu) ### How we reviewed this article: History Share this article [](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.medicalnewstoday.com%2Farticles%2Fmodernas-mrna-flu-vaccine-approved-fda-when-available%3Futm_medium%3Dsocial%26utm_source%3Dfacebook%26utm_campaign%3Dsocial-sharebar-referred-desktop "Share on Facebook") [](https://twitter.com/intent/tweet?via=mnt&text=New%20flu%20vaccine%3A%20Moderna's%20mRNA%20vaccine%20approve
## Related Clinical Research

- [MMR vaccines: separating measles, mumps, rubella shots — myths and facts](https://medichelpline.com/clinical-feed/medical-news-today-0-should-the-measles-mumps-rubella-vaccines-be-separate-myths-vs-facts.md)
- [COVID-19 and Reactivation of Epstein-Barr, Herpes, and Anelloviridae: Study Findings](https://medichelpline.com/clinical-feed/medical-news-today-0-covid-19-may-reactivate-epstein-barr-herpes-viruses-what-this-means.md)
- [Climate change worsens health for people with chronic illness](https://medichelpline.com/clinical-feed/stat-news-1-opinion-climate-change-is-making-people-with-chronic-illness-even-sicker.md)
- [Novartis scores multiple sclerosis outcome with BTK inhibitor](https://medichelpline.com/clinical-feed/stat-news-1-stat-novartis-gets-multiple-sclerosis-win-with-btk-inhibitor.md)
- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.